Skip to content

Donor Funding: $100,000
Cancer Type: Blood cancers
Cancer Stage: Treatment
Funded in: 2020

Professor Tim Hughes
SAHMRI

Even with our current choice of 5 drugs, ~20% of patients with chronic myeloid leukaemia (CML) respond poorly to standard drug therapy.

We plan to develop an algorithm based on the most predictive biological and molecular assays to enable a “precision medicine” approach to CML therapy.

This “risk-adapted” approach would direct most patients to the safest and cheapest therapy whereas “high risk” patients would receive more potent therapy or enter a trial of combination therapy.